Avataan yhtiölle oma ketju. Kuvaus yhtiön sivuilta:
"Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.
The Company’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications.
Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020.
Hansa’s research and development program is advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and has operations in both Europe and the U.S."
Business update 11.1.2012
Redeyen update tänään:
Tätä on tullut ajoittain salkutettua kun aikoinaan tästä Tomi Haatajan blogista luin. Villejä kurssiliikkeitä ja mahdollista pitkän aikavälin potentiaalia.